1-15 of 2657
Albuminuria: An Overlooked Red Flag in Cardiovascular Risk
Conversations in CV Risk AssessmentAlbuminuria: An Overlooked Red Flag in Cardiovascular Risk
Uncovering Cardiovascular Risk in Patients with Target Blood Pressure
Conversations in CV Risk AssessmentUncovering Cardiovascular Risk in Patients with Target Blood Pressure
uACR and eGFR: A Dual-Marker Approach to Cardiovascular Risk Assessment
Conversations in CV Risk AssessmentuACR and eGFR: A Dual-Marker Approach to Cardiovascular Risk Assessment
Rethinking Chronic Kidney Disease: A Key Driver of Cardiovascular Risk
Conversations in CV Risk AssessmentRethinking Chronic Kidney Disease: A Key Driver of Cardiovascular Risk
The Role of Albuminuria in Assessing Cardiovascular Risk
Conversations in CV Risk AssessmentThe Role of Albuminuria in Assessing Cardiovascular Risk
Management of Elevated Albuminuria: Examining Therapeutic Pathways
Conversations in CV Risk AssessmentManagement of Elevated Albuminuria: Examining Therapeutic Pathways
- advertisement
"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
The Convergence"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
Rethinking Schizophrenia Guidelines: Why It’s Time to Incorporate Novel Mechanisms
NeuroFrontiersRethinking Schizophrenia Guidelines: Why It’s Time to Incorporate Novel Mechanisms
Reconnecting With Patients: A Human-Centered Approach to Everyday Practice
Clinician's RoundtableReconnecting With Patients: A Human-Centered Approach to Everyday Practice
Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions
NeuroFrontiersBridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions
Timely Surgery for Hip Fractures: Addressing Anticoagulant Challenges
Clinician's RoundtableTimely Surgery for Hip Fractures: Addressing Anticoagulant Challenges
"I think we're the bridge between the healthcare systems, the pharma systems, and the molecular diagnostic systems," says Matt Newman with Manifold
The Convergence"I think we're the bridge between the healthcare systems, the pharma systems, and the molecular diagnostic systems," says Matt Newman with Manifold
- advertisement
Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
On the Frontlines of SchizophreniaNegative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients
NeuroFrontiersAdvancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiersUsing fMRI to Identify Early Alzheimer’s Disease Subgroups
